Literature DB >> 23689241

Challenges of C1-inhibitor concentrate self-administration.

H B Boysen1, L Bouillet, E Aygören-Pürsün.   

Abstract

Self-administration of therapy can help hereditary angioedema (HAE) patients regain control of their disease or reduce its impact and improve the quality of their lives. However, data from a self-administration survey, and subsequent discussion at an international HAE expert meeting, identified several barriers to self-administration therapy. These barriers include difficulty in administration technique, availability of nursing resources and the mental capacity of the patient. Encouragingly, international HAE experts identified that once a patient has acquired self-administration skills, they generally retain them in the long-term. As patient uptake increases, it was recommended that follow-up management plans should be established to address any issues from the patient's perspective.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689241     DOI: 10.1159/000351238

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema.

Authors:  Rosanna Spanò; Nadia Di Paola; Maria Bova; Alessandro Barbarino
Journal:  BMC Health Serv Res       Date:  2018-07-20       Impact factor: 2.655

2.  Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Authors:  Elyse Murphy; Christine Donahue; Laurel Omert; Stephanie Persons; Thomas J Tyma; Joseph Chiao; William Lumry
Journal:  Nurs Open       Date:  2018-08-28

3.  Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial.

Authors:  Nicolas Javaud; Olivier Fain; Isabelle Durand-Zaleski; David Launay; Laurence Bouillet; Anne Gompel; Alain Sobel; Maguy Woimant; Hasina Rabetrano; Tomislav Petrovic; Frédéric Lapostolle; Isabelle Boccon-Gibod; Paul-Georges Reuter; Philippe Bertrand; Brigitte Coppere; Bernard Floccard; Gisele Kanny; Ludovic Martin; Eric Vicaut; Frédéric Adnet
Journal:  Trials       Date:  2016-04-30       Impact factor: 2.279

Review 4.  Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.

Authors:  Huamin Henry Li
Journal:  Patient Prefer Adherence       Date:  2016-09-07       Impact factor: 2.711

5.  Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.

Authors:  Anette Bygum; Inmaculada Martinez-Saguer; Murat Bas; Jeffrey Rosch; Jonathan Edelman; Mikhail Rojavin; Debora Williams-Herman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

6.  Practicalities of a reduced volume formulation of a C1-INH concentrate for the treatment of hereditary angioedema: real-life experience.

Authors:  John Dempster
Journal:  Allergy Asthma Clin Immunol       Date:  2018-10-25       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.